ArticleThe New England journal of medicine2011
Chimeric antigen receptor-modified T cells in CLL.
Article in The New England journal of medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03240328 (The Effect of CAR-T Cell Therapy on the Reconstitution of HIV-specific Immune Function), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of CAR-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
Who cites it
9 citing papers in PubMed.
- CD81 costimulation skews CAR transduction toward naive T cells.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.Frontiers in immunology · 2020Review
- Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Protein & cell · 2017Review
- Role of the tumor microenvironment in mature B-cell lymphoid malignancies.Haematologica · 2016Review
- Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.Cancer immunology research · 2015Article
- Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.Leukemia · 2014Article
- TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy.Molecular therapy. Nucleic acids · 2013Article
- Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape.Human gene therapy · 2012Article
- Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.